Substituted benzamides and their uses

1. A compound of Formula Va:

or a pharmaceutically acceptable salt, hydrate, solvate, enantiomer, or stereoisomer thereof;

wherein:

F is a heteroaryl selected from pyridine, pyrazine, pyridazine, pyrimidine, 1,2,4-triazine or 1,3,5-triazine, optionally substituted with halogen, hydroxyl group, —CF3 group, C1-C6 alkoxy group, C1-C6 straight chain alkyl, C3-C6 branched chain alkyl or C3-C6 cycloalkyl group, wherein the number of substituents does not exceed the number of available C—H bonds of the heteroaryl; with multiple substitutions, each substituent on the heteroaryl is independent of the other substituents;

m is an integer ranging from 0 to 3;

p is an integer ranging from 1 to 5;

H is selected from —S(O)n-(CH2)q-, —O—(CH2)q-, or —C(O)—(CH2)q-;

n is an integer ranging from 0 to 2;

q is an integer ranging from 0 to 5;

K is selected from (i) C3-C7 cycloalkyl optionally substituted with two or more of R14, R15, and R16, (ii) C1-C6 straight or branched alkyl optionally substitiuted with one or more of R14, R15 and R16, and (iii)

R13 is selected from H, C1-C6 straight chain alkyl, C3-C6 branched chain alkyl or C3-C6 cycloalkyl;

R20 is selected from H, —CF3, C1-C6 straight chain alkyl, C3-C6 branched chain alkyl or C3-C6 cycloalkyl;

R14, R15 and R16 can independently be H, C1-C6 straight chain alkyl, C3-C6 branched chain alkyl, C1-C6 hydroxyalkyl, C1-C6 alkoxy, alkoxyalkyl in which the alkoxy and alkyl portions each independently contain from 1 to 6 carbon atoms, alkoxyalkoxy in which the alkoxy portions each independently contain from 1 to 6 carbon atoms, halogen, —OH, —NH 2 , —CF3, C1-C6 monoalkylamino, C1-C6 dialkylamino, and nitrogen containing heterocycles optionally substituted with one or more of R17 and R18; or

wherein X can be a bond, O, S or NR 19 ;

R17, R18 and R19 are independently selected from H, C1-C6 straight chain alkyl, C3-C6 branched chain alkyl, C3-C6 cycloalkyl, C1-C6 hydroxyalkyl, alkoxyalkyl in which the alkoxy and alkyl portions each independently contain from 1 to 6 carbon atoms, —CF3, or —C(O)O—, or R17 and R18 can be taken together to form a 4 to 7 membered monocycloalkyl ring or 8-14 bicycloalkyl ring, each optionally containing between 1-3 heteroatoms selected from N, O or S, or;

r is an integer ranging from 0 to 3;

t is an integer ranging from 1 to 2; and

u is an integer ranging from 1 to 6.

2. The compound according to claim 1 , wherein F is selected from the group consisting 2-pyrazinyl, 2-pyrimidinyl, 2-pyridinyl, 3-pyridinyl, and 4-pyridinyl, each of which is optionally substituted.

3. The compound according to claim 2 , wherein F is selected from 2-pyridinyl, 3-pyridinyl, and 4-pyridinyl.

4. The compound according to claim 1 , wherein H is —SO 2 —.

5. The compound according to claim 1 , wherein R13 is hydrogen or C1-C6 straight chain alkyl.

6. The compound according to claim 1 , wherein K is

7. A pharmaceutical composition comprising a compound of claim 1 , and pharmaceutically acceptable carrier.

8. The compound of claim 1 , which is

wherein, in Formula Va:

F is pyridin-3-yl;

m is 1;

p is 1;

H is—S(O)n-(CH2)q-, wherein n is 2 and q is 0;

K is,

wherein r is 2, R14 and R15 are both H, and R17 is isobutyl to give 1-isobutylpiperidin-4-yl;

R13 is H; and

R20 is methyl.

9. A pharmaceutical composition comprising the compound of claim 8 , and a pharmaceutically acceptable carrier.